Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
Sponsor: Icahn School of Medicine at Mount Sinai
Listed as NCT03506477, this PHASE4 trial focuses on Plaque Psoriasis and Psoriasis and remains completed. Sponsored by Icahn School of Medicine at Mount Sinai, it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE4
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Jun 2019 — Dec 2019 [monthly]
Recruiting PHASE4
-
Jul 2018 — Jun 2019 [monthly]
Recruiting PHASE4
-
May 2018 — Jul 2018 [monthly]
Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Icahn School of Medicine at Mount Sinai
For direct contact, visit the study record on ClinicalTrials.gov .